Piotr Smolewski

6/8 Mazowiecka Street
Lodz, LD 92215, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Cytotoxic Activity of Melatonin Alone and in Combination with Doxorubicin and/or Dexamethasone on Diffuse Large B-Cell Lymphoma Cells in In Vitro Conditions.

Cytotoxic Activity of Melatonin Alone and in Combination with Doxorubicin and/or Dexamethasone on Diffuse Large B-Cell Lymphoma Cells in In Vitro Conditions.

Journal: Journal of personalized medicine

Published: August 05, 2023

Autoimmune cytopenias in patients with malignant lymphoma: A multicenter report by the Polish Lymphoma Research Group.

Autoimmune cytopenias in patients with malignant lymphoma: A multicenter report by the Polish Lymphoma Research Group.

Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University

Published: July 05, 2023

Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?

Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?

Journal: Expert opinion on pharmacotherapy

Published: November 11, 2022

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

Journal: The New England journal of medicine

Published: July 13, 2022

Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies.

Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies.

Journal: Cancers

Published: June 13, 2022

Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia-A Multicenter Report by the Polish Lymphoma Research Group.

Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia-A Multicenter Report by the Polish Lymphoma Research Group.

Journal: Journal of clinical medicine

Published: May 31, 2022

The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.

The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.

Journal: Cancers

Published: December 15, 2021

Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma.

Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma.

Journal: Expert opinion on pharmacotherapy

Published: February 01, 2021

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.

Journal: Cancers

Published: January 23, 2021

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

Journal: The Lancet. Haematology

Published: January 08, 2021

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.

Journal: Cancers

Published: July 22, 2020

Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.

Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.

Journal: Expert opinion on pharmacotherapy

Published: July 21, 2020

Showing 1-12 of 88

Last Updated: 09/26/2026